Aligos Therapeutics vs Humacyte
Aligos Therapeutics reported revenue of $2 million in fiscal 2025, about the same as Humacyte's $2 million in fiscal 2025. Aligos Therapeutics had an operating margin of -4024.9%, against -5306.0% at Humacyte.
Side by side
| Aligos Therapeutics | Humacyte | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $2M | $2M |
| Revenue growth | −39.5% | — |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | −376.1% |
| Operating margin | −4,024.9% | −5,306.0% |
| Net margin | −1,106.7% | −2,003.6% |
| Free cash flow | — | −$106M |
| Free cash flow margin | — | −5,197.6% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 57.8% | 33.5% |
| Last close | $1.25 | $0.54 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | bought $89,990, sold $41,298 |
| Piotroski F-score | — | 3 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Aligos TherapeuticsHumacyte
Operating margin
Percent of revenue
Aligos TherapeuticsHumacyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aligos TherapeuticsHumacyte
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aligos Therapeutics and Humacyte pages.